AstraZeneca’s Calquence Regimen Approved in EU for Untreated CLL

The latest update is out from AstraZeneca ( (GB:AZN) ).

AstraZeneca has received approval from the European Union for a fixed-duration regimen of its drug Calquence, in combination with venetoclax, with or without obinutuzumab, for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). This approval is based on positive results from the AMPLIFY Phase III trial, which demonstrated significant improvements in progression-free survival compared to standard chemoimmunotherapy. The approval provides a new all-oral treatment option that may help minimize long-term side effects and improve adherence, potentially impacting AstraZeneca’s market position in the oncology sector.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £190.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on GB:AZN Stock

According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.

AstraZeneca’s overall score is driven by strong financial performance and positive corporate developments. While technical indicators and valuation present moderate concerns, the company’s strategic advancements and robust earnings outlook provide a solid investment case.

To see Spark’s full report on GB:AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK. It focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.

Average Trading Volume: 2,555,499

Technical Sentiment Signal: Hold

Current Market Cap: £165B

Learn more about AZN stock on TipRanks’ Stock Analysis page.